Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays

A. E. Takemori, G. Y. Ho, J. S. Naeseth, P. S. Portoghese

Research output: Contribution to journalArticlepeer-review

400 Scopus citations

Abstract

Previously, we reported on an opioid antagonist, nor-binaltorphimine (nor-BNI), that had high selectivity for kappa opioid receptors in smooth muscle preparations. In this study, nor-BNI administered either s.c. or i.c.v. was shown to antagonize significantly the antinociceptive effects of the kappa opioid agonists, ethylketazocine and U-50,488H at doses that had no effect on the antinociceptive effect of mu agonists, morphine and [D-Ala3, MePhe4, Gly-ol5]enkephalin and the delta agonist, [D-Pen3, D-Pen5]enkephalin. Nor-BNI and U-50,488H were used to demonstrate that kappa opioid receptors in the spinal cord were more important than those located supraspinally for kappa-mediated analgesia. Nor-BNI also possessed high affinity and high selectivity for kappa opioid receptors in the receptor binding assay. However, the comparatively low selectivity of BNI in receptor binding studies did not correlatet with the high pharmacologic selectivity for kappa receptors.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalJournal of Pharmacology and Experimental Therapeutics
Volume246
Issue number1
StatePublished - Jan 1 1988

Fingerprint Dive into the research topics of 'Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays'. Together they form a unique fingerprint.

Cite this